Skip to main content
INCY
NASDAQ Life Sciences

UK Approves Incyte's Retifanlimab for Advanced Merkel Cell Skin Cancer

Tom Rudovsky · Reported by Reuters
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$117.28
Mkt Cap
$23.347B
52W Low
$66.85
52W High
$118.69
52W Position info
75% above low
Off High info
1.2% below high
Rel. Volume info
1.6× avg
Market data snapshot near publication time

INCY sits 75% above its 52-week low of $66.85.

Summary

Incyte's Retifanlimab (Zynyz) has received approval from the UK's MHRA for advanced Merkel Cell Skin Cancer. This expands the drug's market access into a major European country, adding a new revenue stream for the company's oncology division. The approval provides a new treatment option for a rare but aggressive cancer. This positive regulatory news continues a strong run for Incyte, following recent FDA approvals and significant pipeline acquisitions.

At the time of this announcement, INCY was trading at $117.28 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $23.3B. The 52-week trading range was $66.85 to $118.69. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.


Price Chart

Share this article

Copied!

INCY - Latest Insights

INCY
Oct 29, 2026, 4:03 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $116.80
Real-time Price: $120.02 info
Change: +$3.22 (+3%) info
Market Cap: $24.658B info
INCY
Oct 29, 2026, 11:07 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $115.20
Real-time Price: $120.02 info
Change: +$4.82 (+4%) info
Market Cap: $24.658B info
INCY
Oct 29, 2026, 7:00 AM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $117.76
Real-time Price: $120.02 info
Change: +$2.26 (+2%) info
Market Cap: $24.658B info
INCY
Aug 31, 2026, 4:34 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $123.22
Real-time Price: $120.02 info
Change: -$3.20 (-3%) info
Market Cap: $24.658B info
INCY
Jul 29, 2026, 6:00 AM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $119.00
Real-time Price: $120.02 info
Change: +$1.02 (+0.86%) info
Market Cap: $24.658B info